CD38
Drug
GENZYME CORPORATION
Total Payments
$688,542
Transactions
638
Doctors
103
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $576,147 | 490 | 91 |
| 2018 | $87,253 | 97 | 24 |
| 2017 | $25,143 | 51 | 17 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $571,861 | 101 | 83.1% |
| Unspecified | $62,211 | 108 | 9.0% |
| Travel and Lodging | $41,135 | 171 | 6.0% |
| Food and Beverage | $13,336 | 258 | 1.9% |
Payments by Type
General
$626,331
530 transactions
Research
$62,211
108 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase I Trial of Isatuximab Monotherapy in the Treatment of Refractory Multiple Myeloma | SANOFI-AVENTIS U.S. LLC | $9,713 | 4 |
| Final results of a Phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM) | SANOFI-AVENTIS U.S. LLC | $7,936 | 6 |
| ICARIA Phase III study design: isatuximab plus pomalidomide (Pom)/dexamethasone (Dex) vs Pom/Dex in relapse/refractory multiple myeloma | SANOFI-AVENTIS U.S. LLC | $7,165 | 2 |
| A Phase Ib study of isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma | SANOFI-AVENTIS U.S. LLC | $6,807 | 7 |
| A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | SANOFI-AVENTIS U.S. LLC | $5,616 | 11 |
| Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma | SANOFI-AVENTIS U.S. LLC | $3,937 | 2 |
| Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). | SANOFI-AVENTIS U.S. LLC | $3,937 | 2 |
| Final results of a Phase Ib study of isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma | SANOFI-AVENTIS U.S. LLC | $3,153 | 7 |
| A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) | SANOFI-AVENTIS U.S. LLC | $2,842 | 6 |
| Updated results from a Phase Ib study of isatuximab plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM) | SANOFI-AVENTIS U.S. LLC | $2,537 | 2 |
| Phase I Trial of Isatuximab, an Anti-CD38 Monoclonal Antibody, in the Treatment of Refractory Hematologic Malignancies Including Multiple Myeloma | SANOFI-AVENTIS U.S. LLC | $2,336 | 4 |
| A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | SANOFI-AVENTIS U.S. LLC | $1,899 | 6 |
| ICARIA-MM | SANOFI-AVENTIS U.S. LLC | $1,010 | 2 |
| A Phase 2 multicenter open-label trial of coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy | SANOFI-AVENTIS U.S. LLC | $974.40 | 2 |
| Isatuximab + Pomalidomide & Dexamethasone combination study | SANOFI-AVENTIS U.S. LLC | $948.96 | 6 |
| Isatuximab + lenalidomide & dexamethasone combination study | SANOFI-AVENTIS U.S. LLC | $718.80 | 8 |
| Results from a phase II study of isatuximab as a single agent and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma | SANOFI-AVENTIS U.S. LLC | $681.42 | 3 |
Top Doctors Receiving Payments for CD38
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Rock Hill, SC | $36,150 | 19 |
| , M.D | Hematology | Scottsdale, AZ | $28,450 | 21 |
| , MD | Hematology & Oncology | Nashville, TN | $21,313 | 19 |
| , M.D | Medical Oncology | Baltimore, MD | $20,104 | 16 |
| , MD | Medical Oncology | Boston, MA | $17,130 | 18 |
| , MD | Hematology & Oncology | Boston, MA | $15,522 | 17 |
| , M.D., F.A.C.P.E | Medical Oncology | Minneapolis, MN | $14,421 | 11 |
| , MD | Hematology & Oncology | Charlotte, NC | $12,913 | 16 |
| , MD | Student in an Organized Health Care Education/Training Program | Birmingham, AL | $12,228 | 8 |
| , MD | Internal Medicine | Seattle, WA | $12,214 | 16 |
| , M.D | Hematology & Oncology | New York, NY | $12,155 | 18 |
| , M.D | Internal Medicine | Spartanburg, SC | $12,151 | 19 |
| , M.D | Internal Medicine | San Francisco, CA | $12,002 | 8 |
| Luciano Costa | Hematology & Oncology | Birmingham, AL | $11,866 | 7 |
| Joseph Bailes | — | Austin, TX | $11,395 | 9 |
| , MD | Internal Medicine | Jasper, AL | $10,715 | 10 |
| , M.D | Medical Oncology | Tampa, FL | $10,460 | 9 |
| , MD | Medical Oncology | Saint Louis, MO | $10,432 | 19 |
| , MD | Medical Oncology | Columbus, OH | $9,847 | 8 |
| , MD | Internal Medicine | Charlotte, NC | $9,776 | 9 |
| , MD | Hematology & Oncology | Tampa, FL | $9,424 | 12 |
| , M.D | Medical Oncology | Boston, MA | $9,382 | 9 |
| , MD | Hematology & Oncology | Milwaukee, WI | $9,263 | 8 |
| , MD | Hematology & Oncology | Denver, CO | $9,173 | 11 |
| , M.D | Hematology & Oncology | Durham, NC | $9,089 | 8 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $626,228
- SANOFI-AVENTIS U.S. LLC $62,315
Product Information
- Type Drug
- Total Payments $688,542
- Total Doctors 103
- Transactions 638
About CD38
CD38 is a drug associated with $688,542 in payments to 103 healthcare providers, recorded across 638 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2019. In 2019, $576,147 was paid across 490 transactions to 91 doctors.
The most common payment nature for CD38 is "Consulting Fee" ($571,861, 83.1% of total).
CD38 is associated with 17 research studies, including "A Phase I Trial of Isatuximab Monotherapy in the Treatment of Refractory Multiple Myeloma" ($9,713).